Andrea Lobo, PhD, science writer —

Andrea Lobo holds a PhD in cell biology/neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She has authored multiple research papers in peer-reviewed journals.

Articles by Andrea Lobo

Bahrain center soon to treat first SCD patient with Casgevy

The Bahrain Oncology Center now is among the first in the world to offer Casgevy (exagamglogene autotemcel), an approved gene-editing therapy, to people with sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), a related blood disorder. That milestone, announced in a release by the country’s regulatory authority,…

Conditional approval of Adakveo for SCD now revoked in UK

Novartis is recalling its sickle cell disease (SCD) treatment Adakveo (crizanlizumab) in the U.K., after the nation’s drug regulatory agency revoked the conditional approval it had previously granted to the antibody-based therapy. The U.K. Medicines & Healthcare products Regulatory Agency (MHRA) made its decision based on Adakveo’s failure…

Menstrual cycles can be heavy, painful for young women with SCD

Heavier menstrual bleeding and pain during menstrual periods appear to be prevalent among adolescents and young women with sickle cell disease (SCD), affecting their quality of life, but few of these patients use hormonal therapies to help regulate their cycles, a single-site U.S. survey study reported. Knowledge of what…

FDA clears device to quickly, accurately ID hemoglobin variants

The U.S. Food and Drug Administration (FDA) has cleared for use Trinity Biotech’s Premier Resolution System, an automated analyzer that can quickly and accurately detect and quantify hemoglobin variants. Hemoglobin is the protein that red blood cells use to carry oxygen through the bloodstream. Several hemoglobin variants identified…